Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Growing evidence shows that dietary interventions can be effective at treating or delaying some diseases, but further trials are needed for wider adoption.
Growing evidence shows that lower doses or shorter treatments of precision cancer therapies could reduce toxicity and save money — but more clinical trials are needed.
Advances in organoids and the role of the microbiome and diet are leading to new diagnostics and treatments for endometriosis, motivating a precision health approach to this long-neglected disease.
High financial costs and limited evidence restrict the adoption of robotic surgery, but new uses for robots and attempts to assess efficacy could widen access.
CAR T cell therapy has transformed the treatment of B cell cancers and is now being pursued by biotech companies for conditions as varied as systemic lupus erythematosus, diabetes and organ rejection.
Many countries are short of healthcare workers, thousands of whom have quit since the COVID-19 pandemic, but the global migration of doctors and nurses to work in high-income countries is hurting the world’s poorest people.
Systematic reviews and meta-analyses are used by clinicians and policymakers to synthesize medical evidence, but they can amplify falsified or poor-quality clinical trial data. In this era of contested evidence, new approaches are needed.
Nigeria’s new mental health act establishes human rights protections for patients and promotes community-based care, offering a roadmap for other countries, despite ongoing challenges.
The US Food and Drug Administration has reduced requirements for preclinical animal testing, leading to a surge of interest in organoids, tissue chips and in silico testing.
Telehealth is poised to grow into big business in Africa, with home-grown and imported start-ups offering child and maternal health education, remote diagnosis, prescription services and more.
A desire for better work conditions and real-world impact are behind the movement, which may hinder academic clinical trials while leading to beneficial collaborations.